leadf
logo-loader
viewSeelos Therapeutics

Seelos Therapeutics initiates preclinical study of SLS-004 in Parkinson’s disease

The study will focus on repression of the SNCA gene, which has been implicated as a highly significant risk factor in Parkinson's

Seelos Therapeutics - Seelos Therapeutics initiates preclinical study of SLS-004 in Parkinson’s disease
Seelos is constructing a system harboring endogenous alpha-synuclein, a protein of interest to Parkinson's researchers

Seelos Therapeutics Inc (NASDAQ:SEEL) said it has initiated a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene.

Seelos said it is constructing a bimodular viral system harboring an endogenous alpha-synuclein (α-synuclein) transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related pathologies.

READ: Seelos Therapeutics to host key opinion leader call to discuss unmet medical needs in suicide and depression

α-synuclein is a protein of interest to Parkinson's researchers because it is a major constituent of Lewy bodies and Lewy neurites, protein clumps that are the pathological hallmark of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).

The company said that it had been previously shown that enrichment in DNA methylation at intron 1 of the α-synuclein gene SNCA, through SLS-004, facilitated "robust and precise repression of SNCA expression". The SNCA gene has been implicated as a highly significant risk factor for PD.

In a statement, Seelos chairman and chief executive Raj Mehra said: “There has been a high level of interest in the alpha-synuclein approach to Parkinson's and beginning further work on our first gene therapy program is exciting. Initiating this preclinical study earlier than expected is also very significant."

Contact the author at calum@proactiveinvestors.com

Follow him on Twitter @Cal_Proac

Quick facts: Seelos Therapeutics

Price: 0.655 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $34.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MagicMed CEO talks the past, present, and most importantly the future of...

MagicMed Industries CEO Dr Joseph Tucker joined Steve Darling from Proactive Vancouver to have a look at where his industry had been in the past, where things are at right now and where he sees the future of Pshycadelics going into the future.           

3 days, 11 hours ago

2 min read